Emerging markets pharma KELIX bio sold to Mubadala
KELIX bio, an emerging markets biopharmaceuticals platform, has been sold to Mubadala Investment Company, an Abu Dhabi investor with over $276 billion in assets under management.
The announcement was made by the current owners of the drugmaker - based Development Partners International (DPI), a premier investment firm focused on Africa, British International Investment (BII), the UK government’s Development Finance Institution, and the European Bank for Reconstruction and Development (EBRD), who sold 100% of the shares. The value of the deal was not disclosed.
The transaction is set to be one of the largest private equity exits and M&A deals in the pharmaceutical sector in Africa over the last twenty years
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze